Four UAMS postdoctoral trainees recently became the inaugural recipients of the Translational Research Institute (TRI) Health Science Innovation & Entrepreneurship (HSIE) Postdoctoral Scholars Program Awards.

Funded by TRI’s Clinical and Translational Science Award (CTSA) TL1 Program, the 15-credit graduate entrepreneurship training includes a significant new partnership with the University of Arkansas, Fayetteville, Sam M. Walton College of Business, which will provide distance education courses to the scholars. The scholars will work with MBA student teams at the UA to develop commercialization plans for health-science technologies conceived at UAMS.

The program spans two years as a complement to the scholars’ existing mentored research training.

The scholars and their research mentors are:

• Samir Jenkins, Ph.D., (mentor, Robert Griffin, Ph.D., Department of Radiation Oncology); interests in nanomaterials and stem cell differentiation.
• Astha Malhotra, Ph.D., (mentor, Jay Mehta, M.D., Ph.D., Department of Internal Medicine, Cardiology); interests in 3-D printing and tissue regeneration.
• Melody Penning, Ph.D., (mentor, Fred Prior, Ph.D., Department of Biomedical Informatics); interests in algorithms to predict adverse events in health care.
• Aaron Storey, Ph.D., (mentor, Ricky Edmondson, Ph.D., Department of Biochemistry and Molecular Biology, Cancer Institute – Proteomics); interests in mass spectrometry to identify bacteria in synovial fluid.

Andrea Edwards, a graduate student in Kevin Raney’s lab was selected to give both an oral and a poster presentation at the NAD+ Metabolism and Signaling Conference in Dublin, Ireland.

Effect of Sulforaphane and 5-Aza-2′-Deoxycytidine on Melanoma Cell Growth.

Chiang TC, Koss B, Su LJ, Washam CL, Byrum SD, Storey A, Tackett AJ.

Medicines (Basel). 2019 .

 

 

 

Direct quantification of the translocation activities of Saccharomyces cerevisiae Pif1 helicase.

Dr. Robert Eoff has received a new, four-year grant award from the NSF.  The award is for ~1.2 million to study “Replication of G-quadruplex DNA by translesion polymerases”.  Dr. Julie Gunderson of Hendrix College is co-Investigator on the grant.

Andrea Edwards, a graduate student in Kevin Raney’s lab was selected as a Southern Regional Education Board SREB-Doctoral Scholars Program recipient for 2019-2020.   Her graduate studies will be funded through a partnership arrangement between SREB, the State of Arkansas, and the University of Arkansas for Medical Services.  She will also have her expenses paid to attend the annual Institute on Teaching and Mentoring.  Congratulations Andrea!

Dr. Magdalena Delgado who recently completed her Ph.D. in Dr. Tim Chamber’s lab has been awarded the Alan D. Elbein Award for Research Excellence.  The award is named in honor of Dr. Alan D. Elbein, who was Chair of the Department of Biochemistry & Molecular Biology from 1991 until 2009 and is given to graduate students that have shown extraordinary research performance during their graduate career. Areas of evaluation include but are not limited to fellowships, manuscripts, and presentations of research.  Congratulations Dr. Delgado!

Ten undergraduate students who are spending their summer in the UAMS Biochemistry and Molecular Biology Department doing research projects presented their work at the SURF Mid-Summer Symposium.

See story on KARK

Alan Tackett, Ph.D., a cancer researcher at the University of Arkansas for Medical Sciences (UAMS), has received a five-year $1.75 million grant from the National Cancer Institute (NCI) to identify new tumor targets in the treatment of metastatic melanoma.

Tackett is a professor in the UAMS College of Medicine Department of Biochemistry and Molecular Biology and serves as associate director of basic research in the UAMS Winthrop P. Rockefeller Cancer Institute.

Although melanoma is less common than other forms of skin cancer, it is the most deadly form of the disease. About 96,480 Americans – including 760 Arkansans – are estimated to be diagnosed with melanoma of the skin in 2019. While not all of these cases will metastasize, or move to other areas of the body, for those that do, treatment options are limited and often unsuccessful.

In recent years, a type of immunotherapy known as immune checkpoint inhibition has shown unprecedented success in the treatment of metastatic melanoma. Immunotherapy harnesses the body’s natural immune system to seek and destroy cancer.

However, while immunotherapies, such as the drugs Keytruda and Opdivo, are successful for many patients, others fail to receive the same positive outcome.

“While these new therapies show great promise for many people, approximately half of metastatic melanoma patients do not respond to immune checkpoint inhibitors. My laboratory is focused on understanding why some patients do not respond to these immunotherapies, so we can use that information to turn these patients into responders” said Tackett, who holds the Scharlau Family Endowed Chair for Cancer Research at UAMS.

To accomplish this task, Tackett uses a sophisticated approach called proteomics that allows his team to measure molecular changes in melanoma cells at the atomic level.

In 2016, Tackett received funding from the National Institutes of Health to implement a National Resource for Proteomics at UAMS, which provides a biomarker discovery platform to researchers at UAMS, as well as those in 23 other states and Puerto Rico.

“By defining pathways active in certain types of melanomas, we can identify new targets for drug development that could increase responsiveness to immune checkpoint inhibitors and thereby save the lives of thousands of patients each year,” said Tackett, whose research has been highly funded by the National Institutes of Health for his entire career.

To accomplish its research, Tackett’s team works closely with UAMS surgeons, oncologists and pathologists to obtain fresh tumor samples removed during surgery at UAMS Medical Center.

“Getting fresh tissue out of surgery and into our lab very quickly is key. This gives us the ability to sort it into individual cell populations and analyze it in ways that are difficult to do with older, fixated tissue samples,” he said.

New patients at the UAMS Winthrop P. Rockefeller Cancer Institute are asked in the early stages of treatment about their interest in donating a portion of their surgically removed tumor, or other specimen such as blood or urine, to benefit research.

The procurement of donated tumor tissue does not require any type of additional procedure, but makes use of a portion of the tissue that was removed during the normal surgical process.

“The research environment at UAMS is ideal for these types of studies as basic scientists work seamlessly with clinicians to move research from the lab to the clinic as quickly as possible,” said Tackett.

This federal grant will bolster the Cancer Institute’s ongoing efforts to receive National Cancer Institute Designation, which requires the institution achieve at least $20 million in annual direct cost research funding from an approved list of funding agencies.

To achieve designation, cancer centers undergo a highly competitive assessment process that demonstrates an outstanding depth and breadth of research in three areas: basic laboratory, patient/clinical and population-based. The designation brings with it many benefits, including expanded access to federal funding for researchers and improved access to clinical trials for patients.

Congratulations to Allie Davis and Alicja Urbaniak, Ph.D. for winning the poster competitions at the Drug Discovery and Development Colloquium on June 13-16.  Allie is a student in Dr. Paul Miller’s lab, and she won the Outstanding Graduate Student Poster Presentation for her poster entitled “BIOACTIVATION OF HALOGENATED AROMATIC DRUGS AS A PRECURSOR TO DRUG-INDUCED HEPATOTOXICITY”.  Dr. Urbaniak is a postdoctoral fellow in Dr. Tim Chamber’s lab, and she won the first place poster presentation in the postdoctoral fellow category for her poster entitled ” ACTIVITY OF COLCHICINE DERIVATIVES TOWARDS PRIMARY ALL AND BREAST CANCER CELLS”.